Skip Navigation

Japanese Journal of Clinical Oncology 2005 35(3):116-120; doi:10.1093/jjco/hyi041
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Isobe, K.
Right arrow Articles by Shigematsu, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Isobe, K.
Right arrow Articles by Shigematsu, N.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2005 Foundation for Promotion of Cancer Research

Hyperfractionated Radiation Therapy for Locoregionally Advanced Nasopharyngeal Cancer

Koichi Isobe1, Takashi Uno1, Hiroyuki Kawakami1, Naoyuki Ueno1, Takashi Aruga1, Shigeo Yasuda1, Toyoyuki Hanazawa2, Yoshitaka Okamoto2, Hisao Ito1 and Naoyuki Shigematsu3

Departments of 1 Radiology and 2 Otorhinolaryngology, Chiba University Hospital, Chiba and 3 Department of Radiology, Keio University, School of Medicine, Tokyo, Japan

For reprints and all correspondence: Koichi Isobe, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan. E-mail: isobeko{at}ho.chiba-u.ac.jp

Received November 9, 2004; accepted January 2, 2005

Objective: The purpose of this study is to clarify the efficacy and toxicity of hyperfractionated radiation therapy (RT) for patients with nasopharyngeal cancer (NPC).

Methods: Twenty-two patients with NPC treated at our hospital between April 1994 and December 2002 were the subjects of this study. They received hyperfractionated RT with a fraction size of 1.2 Gy, with a median tumor dose of 72 Gy (range 64.8–80.4). During this study period, our institutional strategy for locoregionally advanced NPC included neoadjuvant or concurrent chemotherapy combined with hyperfractionated RT, and 17 patients received some forms of cisplatin-containing chemotherapy.

Results: With a median follow-up of 59 months, the estimated 5-year disease-free survival rate and overall survival rate were 72.7 and 85.2%, respectively. Acute hematological toxicities were acceptable and manageable. However, >50% of patients required nutritional support, and experienced severe pharyngitis, skin reaction and body weight loss. With regard to late sequelae, one patient developed grade 3 osteomyelitis, and one patient each developed grade 4 passage disturbance and laryngeal edema. No patients experienced any grades of optic nerve injury or temporal lobe necrosis.

Conclusions: Hyperfractionated RT using 1.2 Gy per fraction, for a total dose of 72 Gy, produces a comparable treatment outcome. Although deleterious neurological sequelae were not observed in this study, caution should be exercised regarding other late sequelae, such as osteomyelitis and passage disturbance.

Key Words: nasopharyngeal cancer (NPC) • hyperfractionation • altered fractionation • late effect


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.